Results 1 to 10 of about 20,376 (164)

Effect of Pegylated Interferon on Non-Responders and Relapsers with Interferon

Sultan Qaboos University Medical Journal, 2002
Objectives: To assess whether a combination of pegylated interferon (interferon conjugated with polyethylene glycol) and ribavirin can improve the response rate in patients with chronic hepatitis C who either did not respond to (Non-responders), or had ...
Hisham O. Akbar, Mahmoud S. Al Ahwal
doaj   +3 more sources

Pegylated interferon: the who, why, and how. [PDF]

Hematology Am Soc Hematol Educ Program
Abstract Interferon alpha (IFN-α) is a fascinating molecule with many biological properties yet to be fully understood. Among these properties, several have demonstrated usefulness for targeting malignant cells, including hematopoietic cells from patients with myeloproliferative neoplasms.
Kiladjian JJ.
europepmc   +3 more sources

Successful treatment of hairy cell leukaemia with pegylated interferon-alpha-2A [PDF]

Pathology and Oncology Research
IntroductionHairy cell leukemia (HCL) is an indolent B-cell lymphoproliferative disease. Interferon-alpha (IFN-alpha) was the first successfully used drug in HCL; its favourable effect has been known since the early 1980s.
Kata Ferenczi, Zsófia Flóra Nagy, Ildikó Istenes, Hanna Eid, Csaba Bödör, Botond Timár, Judit Demeter   +6 more
doaj   +2 more sources

Management of common autoimmune diseases in patients with myeloproliferative neoplasms treated with pegylated interferon alfa—case report, review of the literature and multidisciplinary clinical practice recommendations [PDF]

Therapeutic Advances in Hematology
Pegylated interferons alfa are increasingly used in patients with myeloproliferative neoplasms (MPN) due to their potential disease-modifying effect. Ropeginterferon alfa-2b has been approved for patients with polycythemia vera (PV) with no symptomatic ...
Axel Rüfer, Christoph Brand, Andrea de Gottardi, Stefan Fischli, Ralph Melzer, Urs Odermatt, Walter A. Wuillemin, Sacha S. Zeerleder   +7 more
doaj   +2 more sources

Results of interferon-based treatments in Alaska Native and American Indian population with chronic hepatitis C [PDF]

International Journal of Circumpolar Health, 2016
Background: There have been few reports of hepatitis C virus (HCV) treatment results with interferon-based regimens in indigenous populations. Objective: To determine interferon-based treatment outcome among Alaska Native and American Indian (AN/AI ...
Stephen E. Livingston, Lisa J. Townshend-Bulson, Dana J. T. Bruden, Chriss E. Homan, James E. Gove, Julia N. Plotnik, Brenna C. Simons, Philip R. Spradling, Brian J. McMahon   +8 more
doaj   +1 more source

Importance of adherence for efficacy of hepatitis C combined therapy [PDF]

Srpski Arhiv za Celokupno Lekarstvo, 2013
Introduction. Dual antiviral therapy with pegylated interferon alfa-2a and ribavirin leads do sustained elimination of hepatitis C virus infection in over 50% patients with genotypes 1 and 4 and in over 80% with genotypes 2 and 3.
Nožić Darko, Delić Dragan, Božić Milena, Fabri Milotka, Svorcan Petar, Konstantinović Ljiljana   +5 more
doaj   +1 more source

Screening for hepatitis D and PEG-Interferon over Tenofovir enhance general hepatitis control efforts in Brazil. [PDF]

PLoS ONE, 2018
BACKGROUND:Hepatitis D virus (HDV), which requires the presence of hepatitis B virus (HBV), is a deadly yet neglected disease that rapidly leads to liver cancer and disease-induced mortality.
Ashish Goyal, Ethan Obie Romero-Severson
doaj   +1 more source

Interferon-λ treatment accelerates SARS-CoV-2 clearance despite age-related delays in the induction of T cell immunity

Nature Communications, 2022
The interferon response is a critical component response to SARS-CoV-2 infection and prior studies have established a role for the administration of PEGylated interferon-lambda1 and its impact on viral clearance.
Deanna M. Santer, Daniel Li, Yanal Ghosheh, Muhammad Atif Zahoor, Dhanvi Prajapati, Bettina E. Hansen, D. Lorne J. Tyrrell, Jordan J. Feld, Adam J. Gehring   +8 more
doaj   +1 more source

Thyrotoxicosis With Pegylated Interferon Alfa-2b [PDF]

Archives of Dermatology, 2010
Despite adequate surgery, a diagnosis of stage III melanoma carries a high risk of relapse, and hence mortality. Interferon alfa is the only treatment that has currently been shown to alter the natural history of the disease, delaying relapse-free survival, particularly in patients with micrometastatic disease.
Lowndes, SA, Asher, R, Middleton, MR
openaire   +2 more sources

ASSESSMENT OF SERUM INTERLEUKIN-10 LEVEL IN CHRONIC HEPATITIS C PATIENTS TREATED WITH PEGYLATED INTERFERON AND RIBAVIRIN [PDF]

Kafrelsheikh Veterinary Medical Journal, 2014
Hepatitis C virus (HCV) infection is a major health problem. Egypt has the highest prevalence worldwide. Currently, combined pegylated interferon and ribavirin therapy is the standard treatment but the outcome is not satisfactory. The present study aimed
Nilly Helmy Abdalla, A. M. Okasha, S. R., Abdel raheim, Hannan A. Soliman, S. Z. Abd al aziz   +4 more
doaj   +1 more source